MA35303B1 - Vaccin contre la rhinite equine - Google Patents
Vaccin contre la rhinite equineInfo
- Publication number
- MA35303B1 MA35303B1 MA36241A MA36241A MA35303B1 MA 35303 B1 MA35303 B1 MA 35303B1 MA 36241 A MA36241 A MA 36241A MA 36241 A MA36241 A MA 36241A MA 35303 B1 MA35303 B1 MA 35303B1
- Authority
- MA
- Morocco
- Prior art keywords
- equine rhinitis
- vaccine against
- against equine
- rhinitis
- immunogenic compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La présente invention concerne des compositions immunogènes contre le virus de la rhinite equine, en particulier les virus a et b de la rhinite equine, et des procédés pour leur utilisation et leur préparation. Les compositions immunogènes, dans d'autres modes de réalisation, comprennent également d'autres pathogènes équins.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452390P | 2011-03-14 | 2011-03-14 | |
US201161510226P | 2011-07-21 | 2011-07-21 | |
PCT/US2012/028706 WO2012125525A2 (fr) | 2011-03-14 | 2012-03-12 | Vaccin contre la rhinite équine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35303B1 true MA35303B1 (fr) | 2014-08-01 |
Family
ID=45876924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36241A MA35303B1 (fr) | 2011-03-14 | 2013-09-12 | Vaccin contre la rhinite equine |
Country Status (12)
Country | Link |
---|---|
US (1) | US9187730B2 (fr) |
EP (2) | EP2772266B1 (fr) |
AR (1) | AR085800A1 (fr) |
AU (2) | AU2012229192B2 (fr) |
BR (2) | BR122019023542B1 (fr) |
CA (2) | CA3018230A1 (fr) |
ES (2) | ES2748555T3 (fr) |
MA (1) | MA35303B1 (fr) |
MX (1) | MX350718B (fr) |
NZ (1) | NZ614147A (fr) |
TW (1) | TW201300537A (fr) |
WO (1) | WO2012125525A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2772266B1 (fr) | 2011-03-14 | 2019-07-31 | Boehringer Ingelheim Animal Health USA Inc. | Vaccin contre la rhinite équine |
CA2967532A1 (fr) | 2014-11-24 | 2016-06-02 | Intervet International B.V. | Vaccins du virus de la grippe equine inactive |
US10064930B2 (en) * | 2015-01-16 | 2018-09-04 | Boehringer-Ingelheim Vermedica, Inc. | Immunogenic compositions and methods for pigeon fever |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2702373B1 (fr) | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
AUPN720195A0 (en) | 1995-12-18 | 1996-01-18 | University Of Melbourne, The | Equine rhinovirus 1 proteins |
US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6177082B1 (en) | 1998-08-13 | 2001-01-23 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cold-adapted equine influenza viruses |
US7425437B2 (en) | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
CA2438692C (fr) | 2001-02-28 | 2010-04-27 | Akzo Nobel Nv | Emulsions de type huileux injectables |
AU2002309508A1 (en) | 2001-03-12 | 2002-09-24 | L2 Diagnostics, Llc | Compositions and methods comprising west nile virus polypeptides |
US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
AUPR472501A0 (en) | 2001-05-02 | 2001-05-24 | Council Of The Queensland Institute Of Medical Research, The | Equine rhinitis a virus antigens |
WO2003061555A2 (fr) | 2001-07-27 | 2003-07-31 | Wyeth | Vacccin west nile |
JP5164305B2 (ja) | 2001-10-19 | 2013-03-21 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 動物におけるフラビウイルス感染を予防および治療する方法 |
DE60330708D1 (de) | 2002-11-15 | 2010-02-04 | Sanofi Pasteur Biologics Co | Impfstoff gegen das west-nile-virus |
CA2432738A1 (fr) | 2003-02-26 | 2004-08-26 | Philippe Despres | Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques |
US7585621B2 (en) | 2003-09-09 | 2009-09-08 | Idexx Laboratories, Inc. | Detection of West Nile virus infection and vaccination |
US7459163B2 (en) | 2004-02-25 | 2008-12-02 | University Of Kansas | Infectious DNA as a vaccine against west nile and other flaviviruses |
US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
US7482017B2 (en) | 2004-09-09 | 2009-01-27 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
EP1645283A1 (fr) | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Composition de vaccin combiné |
CA2591665C (fr) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
BRPI0611581B1 (pt) | 2005-06-24 | 2021-08-03 | Intervet International B.V. | Flavivírus quimérico inativado, composição imunogênica, e, vacina |
US7384642B2 (en) | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
US7425336B2 (en) | 2005-08-25 | 2008-09-16 | Mevial Limited | Canine influenza vaccines |
CN101309701A (zh) | 2005-10-07 | 2008-11-19 | 辉瑞产品公司 | 治疗犬流感的疫苗和方法 |
US7468187B2 (en) | 2005-10-18 | 2008-12-23 | Iowa State University Research Foundation, Inc. | Canine influenza virus and related compositions and methods of use |
AU2006310555B2 (en) | 2005-11-01 | 2011-08-04 | Intervet International B.V. | Prime boost vaccine for the protection of equines against equine influenza |
US7455842B2 (en) | 2005-12-05 | 2008-11-25 | University Of Kansas | Chimeric West Nile viruses and uses thereof |
KR100850545B1 (ko) | 2007-10-30 | 2008-08-05 | 주식회사 에니멀제네틱스 | 신규한 개 인플루엔자 바이러스 및 이의 백신 |
WO2010025469A1 (fr) | 2008-08-29 | 2010-03-04 | Boehringer Ingelheim Vetmedica, Inc. | Vaccin contre le virus du nil occidental |
EP2772266B1 (fr) | 2011-03-14 | 2019-07-31 | Boehringer Ingelheim Animal Health USA Inc. | Vaccin contre la rhinite équine |
-
2012
- 2012-03-12 EP EP14164842.8A patent/EP2772266B1/fr active Active
- 2012-03-12 CA CA3018230A patent/CA3018230A1/fr active Pending
- 2012-03-12 CA CA2829226A patent/CA2829226C/fr active Active
- 2012-03-12 MX MX2013010125A patent/MX350718B/es active IP Right Grant
- 2012-03-12 AU AU2012229192A patent/AU2012229192B2/en active Active
- 2012-03-12 BR BR122019023542-2A patent/BR122019023542B1/pt active IP Right Grant
- 2012-03-12 BR BR112013023354-0A patent/BR112013023354B1/pt not_active IP Right Cessation
- 2012-03-12 WO PCT/US2012/028706 patent/WO2012125525A2/fr active Application Filing
- 2012-03-12 NZ NZ614147A patent/NZ614147A/en not_active IP Right Cessation
- 2012-03-12 ES ES14164842T patent/ES2748555T3/es active Active
- 2012-03-12 US US13/417,855 patent/US9187730B2/en active Active
- 2012-03-12 ES ES12710420T patent/ES2842595T3/es active Active
- 2012-03-12 EP EP12710420.6A patent/EP2686012B1/fr active Active
- 2012-03-13 AR ARP120100823A patent/AR085800A1/es active Pending
- 2012-03-13 TW TW101108504A patent/TW201300537A/zh unknown
-
2013
- 2013-09-12 MA MA36241A patent/MA35303B1/fr unknown
-
2017
- 2017-03-06 AU AU2017201526A patent/AU2017201526C1/en active Active
Also Published As
Publication number | Publication date |
---|---|
NZ708320A (en) | 2016-08-26 |
EP2686012B1 (fr) | 2020-12-02 |
BR112013023354A2 (pt) | 2016-12-06 |
ES2748555T3 (es) | 2020-03-17 |
BR122019023542B1 (pt) | 2022-02-15 |
AU2012229192A1 (en) | 2013-08-29 |
AU2012229192B2 (en) | 2017-04-20 |
CA3018230A1 (fr) | 2012-09-20 |
US9187730B2 (en) | 2015-11-17 |
EP2686012A2 (fr) | 2014-01-22 |
CA2829226A1 (fr) | 2012-09-20 |
EP2772266B1 (fr) | 2019-07-31 |
TW201300537A (zh) | 2013-01-01 |
AU2017201526A1 (en) | 2017-03-30 |
AU2017201526B2 (en) | 2019-07-18 |
EP2772266A1 (fr) | 2014-09-03 |
NZ614147A (en) | 2015-08-28 |
AU2017201526C1 (en) | 2019-10-24 |
CA2829226C (fr) | 2023-01-03 |
BR112013023354B1 (pt) | 2022-02-15 |
MX2013010125A (es) | 2013-10-07 |
WO2012125525A2 (fr) | 2012-09-20 |
ES2842595T3 (es) | 2021-07-14 |
AR085800A1 (es) | 2013-10-30 |
US20120237543A1 (en) | 2012-09-20 |
WO2012125525A3 (fr) | 2013-02-28 |
MX350718B (es) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018256602A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
UA104005C2 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
NZ703064A (en) | Inhibitors of hepatitis c virus | |
NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MA35414B1 (fr) | Formulations de vaccin parenteral contre un norovirus | |
MX2010002317A (es) | Derivados de indol sustituidos y metodos para su utilizacion. | |
EP3266464A3 (fr) | Thérapeutique à base de levure pour infection chronique par l'hépatite b | |
MX2010005356A (es) | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. | |
GEP201706698B (en) | Inhibitors of influenza viruses replication | |
CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
MX352604B (es) | Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah. | |
MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
MX2013001237A (es) | Compuestos inhibidores del virus de la hepatitis c. | |
MX2012002925A (es) | Inhibidores de virus flaviviridae. | |
MX2013006170A (es) | Formulaciones virales liquidas. | |
IN2014MN01547A (fr) | ||
MX349294B (es) | Formulaciones virales liofilizadas. | |
WO2010053610A3 (fr) | Formulations stables de vaccin contre l'anthrax | |
EA201290956A1 (ru) | Вакцина против вич | |
WO2011079073A3 (fr) | Vaccins anti-virus herpès simplex | |
WO2012047267A3 (fr) | Immunogène polyvalent | |
UA118542C2 (uk) | Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197 | |
MA37749B1 (fr) | Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine | |
MX347911B (es) | Vacuna contra virus de diarrea viral de bovinos. |